Class / Patent application number | Description | Number of patent applications / Date published |
546122000 | The other cyclo in the bicyclo ring system is also six-membered (e.g., naphthyridines, etc.) | 29 |
20090156822 | Hepatitis C Inhibitor Dipeptide Analogs - Compounds of formula (I): | 06-18-2009 |
20090171089 | 1,6 NAPHTHRIDINES USEFUL AS INHIBITORS OF SYK KINASE - Disclosed are compounds of formula (I): | 07-02-2009 |
20090198063 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF - Disclosed is a compound represented by the general formula: [wherein R | 08-06-2009 |
20090221828 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives - A process for preparing 1-halo-2,7-naphthyridinyl derivatives is described (I), wherein X is Cl or Br; which process comprises the following steps: (i) reaction of a 3-cyano-4-methylpyridine derivative of formula (A): with a compound of formula (II), in the presence of an N,N-dimethylformamide diC | 09-03-2009 |
20100087649 | QUINOLINONE DERIVATIVES - HIV inhibitory compounds of formula (I) including the stereoisomeric forms thereof, the pharmaceutically acceptable salts, and pharmaceutically acceptable solvates thereof; wherein R | 04-08-2010 |
20140256947 | PREPARATION OF AMINOTETRALIN COMPOUNDS - The present invention relates to synthetic processes for preparation of aminotetralin compounds with kinase inhibitory activity. The invention also provides synthetic intermediates useful in the processes of the invention. | 09-11-2014 |
20150025244 | Process for Manufacturing a Naphthyridine Derivative - The invention relates to a process and synthetic intermediates that can be used for manufacturing the compound of formula (1-6) which is a synthetic intermediate useful in the preparation of antibiotic compounds. | 01-22-2015 |
20150031890 | PHARMACEUTICAL COMPOSITION COMPRISING BICYCLIC PYRIDINOL DERIVATIVES FOR PREVENTING OR TREATING DISEASES CAUSED BY ANGIOGENESIS - There is provided a pharmaceutical composition comprising a bicyclic pyridinol derivative as an active ingredient for preventing or treating diseases caused by angiogenesis. The bicyclic pyridinol derivative expressed by Chemical Formula 1 can be effectively used as a drug for preventing and treating diseases caused by angiogenesis since it inhibits neovascularization in a chorioallantoic membrane model. | 01-29-2015 |
20150087840 | Process for Manufacturing Naphthyridine Derivatives - The invention relates to a new process suitable for manufacturing the compounds of formula I (I) wherein W is H, Br, Cl or methyl, which are synthetic intermediates useful in the preparation of antibiotic compounds. | 03-26-2015 |
20150112071 | PREPARATION OF AMINOTETRALIN COMPOUNDS - The present invention relates to synthetic processes for preparation of aminotetralin compounds with kinase inhibitory activity. The invention also provides synthetic intermediates useful in the processes of the invention. | 04-23-2015 |
20150336954 | Process for Manufacturing a Naphthyridine Derivative - The invention relates to a process and synthetic intermediates that can be used for manufacturing the compound of formula (1-6) which is a synthetic intermediate useful in the preparation of antibiotic compounds. | 11-26-2015 |
20160008333 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR POSTERIOR OCULAR DISEASE CONTAINING TETRAHYDROPYRANYLAMINOCYCLOPENTYLCARBONYLTETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS EFFECTIVE INGREDIENT | 01-14-2016 |
20160039833 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). | 02-11-2016 |
546123000 | Chalcogen and -C(=X)-, wherein X is chalcogen, bonded directly to ring carbons of the bicyclo ring system (e.g., 4-oxo-naphthyridine -3-carboxylic acid, etc.) | 16 |
20090105479 | 4-Oxo-1-3-Substituted Phenyl-1,4-Dihydro-1,8-Napthyridene-3-Carboxamide Phosphodiesterase-4 Inhibitor and a Method of Preparing Same - The invention is directed to a compound of the structural formula (22) (22) crystal form of structural formulae (21) and its free acid, pharmaceutical compositions comprising these compounds and methods of preparing and using these compounds. | 04-23-2009 |
20090306389 | Intermediate products for producing oxazolidinone-quinolone hybrids - The present invention describes intermediates (ZP) for a novel and efficient synthesis of compounds in which the pharmacophores of quinolone and oxazolidinone are linked to one another by way of a chemically stable linker. | 12-10-2009 |
20100076193 | PROCESS FOR THE PREPARATION OF GEMIFLOXACIN - The present invention relates to an improved process for the preparation of Gemifloxacin mesylate of formula (V). The present invention further provides novel intermediates of formula (II) and (IV), which are useful intermediates for the preparation of Gemifloxacin mesylate of formula (V). | 03-25-2010 |
20100076194 | SUBSTITUTED 3-AMINO-1-OXO OR THIOXO-1,2,5,6,7,8-HEXAHYDRO-2,7-NAPHTHYRIDINE-4-CARBONITRILES ARE SELECTIVE ALPHA 2B ANTAGONISTS - The present invention provides compounds which are subtype selective antagonists of the alpha 2B adrenergic receptor and have no or weak antagonist activity at the other alpha adrenergic receptors. These compounds are useful as tool compounds and, in particular, as tool compounds for developing compounds useful in treating diseases that include but are not limited to chronic pain, visceral pain, corneal pain, neuropathic pain, glaucoma, ischemic neuropathies and other neurodegenerative diseases and conditions. These compounds are also useful as compounds for treating myocardial infarction and preventing acute coronary events. The compounds of this invention are 3-amino-1-thioxo or oxo-1,2,5,6,7,8-hexahydro-2,7-naphthyridine-4-carbonitriles or substituted derivatives thereof. | 03-25-2010 |
20100197924 | PREPARATION OF AMINOTETRALIN COMPOUNDS - The present invention relates to synthetic processes for preparation of aminotetralin compounds with kinase inhibitory activity. The invention also provides synthetic intermediates useful in the processes of the invention. | 08-05-2010 |
20110152528 | Method For Producing 3,7-Diaza-Bicyclo[3.3.1] Nonane Compounds - The invention relates to a one-pot reaction for the production of 3,7-diaza-bicyclo[3.3.1]nonane compounds, wherein in a first step a dicarboxylic acid ester is reacted with a pyridine aldehyde and a primary amine. The piperidone created in this manner is reacted with formaldehyde and a further primary amine in a second step. It is essential to the invention that both reaction steps are carried out in a one-pot variation in a C | 06-23-2011 |
20120130075 | R-7-(3-AMINOMETHYL-4-METHOXYIMINO-3-METHYL-PYRROLIDIN-1-YL)-1-CYCLOPROPYL-- 6-FLUORO-4-OXO-1,4-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID AND L-ASPARTIC ACID SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR ANTIMICROBIAL - Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration. | 05-24-2012 |
20120259119 | ISATIN DERIVATIVES, MEDICAMENTS CONTAINING THE ISATIN DERIVATIVES AND METHOD FOR ITS PREPARATION - The present invention relates to an isatin derivative having the formula (I), a medicament for treatment of tuberculoses containing that isatin derivative as well as a method for preparing isatin derivative according to formula (I). | 10-11-2012 |
20130190498 | ISATIN DERIVATIVES, MEDICAMENTS CONTAINING THE ISATIN DERIVATIVES AND METHOD FOR ITS PREPARATION - The present invention relates to an isatin derivative having the formula (I), a medicament for treatment of tuberculoses containing that isatin derivative as well as a method for preparing isatin derivative according to formula (I). | 07-25-2013 |
20130190499 | Azaisoquinolinone derivatives as NK3 antagonists - The invention relates to compounds useful in therapy, in particular in the treatment of psychosis, to compositions comprising said compounds, and to methods of treating diseases comprising the administration of said compounds. | 07-25-2013 |
20140046067 | PHARMACOLOGICALLY ACTIVE ALICYCLIC N,N'-SUBSTITUTED 3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES AND DRUGS BASED THEREON - The invention relates to novel alicyclic N,N′-substituted diazabicyclo[3.3.1]nonane derivatives of general formula (I) which act as allosteric AMPA receptor modulators, and to drugs based thereon which can be used for treating Alzheimer's, Parkinson's and other neurodegenerative diseases. | 02-13-2014 |
20140128610 | R-7-(3-AMINOMETHYL-4-METHOXYIMINO-3-METHYL-PYRROLIDIN-1-YL)-1-CYCLOPROPYL-- 6-FLUORO-4-OXO-1,4-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID AND L-ASPARTIC ACID SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR ANTIMICROBIAL - Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration. | 05-08-2014 |
20140275547 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION - Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles. | 09-18-2014 |
20140275548 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS - The invention provides a chemical entity of Formula (I) | 09-18-2014 |
20150080576 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are amide compounds which can be prepared from certain heteroaryl carboxylic acids and certain diazabicycloalkanes. The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α4β2 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle). | 03-19-2015 |
20150105558 | R-7-(3-AMINOMETHYL-4-METHOXYIMINO-3-METHYL-PYRROLIDIN-1-YL)-1-CYCLOPROPYL-- 6-FLUORO-4-OXO-1,4-DIHYDRO-[1,8]NAPHTHYRIDINE-3-CARBOXYLIC ACID AND L-ASPARTIC ACID SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR ANTIMICROBIAL - Disclosed herein are R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial. Because the R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt is more soluble and less toxic and has less side effects as an antimicrobial agent than hydrochloride and the other salts (D-aspartate and phosphate) conventionally used, the salt may be useful for oral and injectable administration. | 04-16-2015 |